CNS pipeline · person
Andrew Miller, PhD
Member of Alto Neuroscience's board of directors (effective May 2026). Founder and former President of R&D / CEO of Karuna Therapeutics and lead inventor of KarXT (marketed by Bristol Myers Squibb as COBENFY for schizophrenia); he guided Karuna through its $14 billion acquisition by Bristol Myers Squibb in 2024.
- 1 company
Courtesy Alto Neuroscience
Current roles
- Alto Neuroscience, Inc.Director · Board2026–present
Appears with
People sharing a company with Andrew.
- Adam Savitz · Alto Neuroscience, Inc.
- Alan Schatzberg · Alto Neuroscience, Inc.
- Amit Etkin · Alto Neuroscience, Inc.
- Andrew Dreyfus · Alto Neuroscience, Inc.
- Christopher Nixon Cox · Alto Neuroscience, Inc.
- Dan Segal · Alto Neuroscience, Inc.
- Erin R. McQuade · Alto Neuroscience, Inc.
- Gwill York · Alto Neuroscience, Inc.
- Husseini Manji · Alto Neuroscience, Inc.
- Jessica Powell · Alto Neuroscience, Inc.
- Madhukar H. Trivedi · Alto Neuroscience, Inc.
- Michael Hanley · Alto Neuroscience, Inc.
- Nick Smith · Alto Neuroscience, Inc.
- Quentin Huys · Alto Neuroscience, Inc.
- Raymond Sanchez · Alto Neuroscience, Inc.
- Tom Insel · Alto Neuroscience, Inc.
People and affiliation data assembled from public company disclosures, SEC filings, and conference materials — every record source-cited under psychiatrist-authored guardrails.